Our team utilizes clinical big dataadvanced AI to expedite optimal treatment guidanceidentify appropriate clinical trials for new drugs in lung cancer patients. Through multimodal prediction methods, we analyze pathology reportsprovide results in just 5 seconds. This approach minimizes treatment delaysenhances shared decision-making among patients, families,healthcare providers for advanced lung cancer.

Our team combines state-of-the-art natural language BERT modelgenerative GPT technology to make important information in pathological reports clearensure the securityprivacy of medical data. Through high-quality healthcare big data, we generate personalized recommendations for optimal treatment drug combinationssuitable new drug clinical trials. This groundbreaking research achievement achieves excellent performance that surpasses international benchmarks.

This technology has broad industrial applicabilityadvantages over international benchmarks. It offers rapid guidance for drug combinationsclinical trial recommendations. We are validating it clinicallyapplying for patents to expedite commercialization. We also plan to promote market application through technology transfer collaborations. Our target market is not limited to Taiwan we aim for international reachwidespread utilization.